Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Annexin Pharmaceuticals AB: BioStock: Annexin comments on acquisition and focus on ANXV in ophthalmology

Annexin Pharmaceuticals

Merck recently announced that they are acquiring the biotech company EyeBio for up to 3 billion USD, thereby strengthening its presence in ophthalmology. EyeBio's drug candidate Restoret is being developed to treat diabetes-related eye diseases. Another active player in the ophthalmology field is the Swedish company Annexin Pharmaceuticals. BioStock reached out to the company's CEO Anders Haegerstrand to get his comments on the acquisition and gain further insights into Annexin's focus for 2024.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/06/annexin-comments-on-acquisition-and-focus-on-anxv-in-ophthalmology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.